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ABSTRACT 
Fluconazole is a synthetic antifungal drug, belonging to triazole group and mostly used to treat oral candidiasis caused by the 
yeast Candida albicans. Fluconazole commercially available in tablets that offer poor bioavailability, due to hepatic first pass effect 
and gastric instability leads to frequent dosing. Buccal drug delivery can bypass such problems of tablet and leads to increase in 
bioavailability. Due to low molecular weight, fluconazole can suitably administered by buccal route, hence local and targeted action 
can achieve. The present study was conducted to develop proniosomal gel of fluconazole by coacervation phase separation method 
using Span 20, cholesterol, soya lecithin, ethanol and aqueous vehicle. Based on preliminary studies surfactant and aqueous vehicle 
was selected. The Box Behnken design was employed to optimized proniosomes by evaluating responses like entrapment efficiency, 
vesicle size and drug release. The optimized proniosomes were evaluated with entrapment efficiency (96.83%), vesicle size (2µm), 
in vitro drug release 85.66 % (3 h) and ex vivo mucosal permeation (85.67 %) with flux (394.09 μg/cm2h). The optimized 
proniosomes were incorporated into 2% w/w Carbopol gel 934 (1:1) to obtain proniosomal gel. This optimized proniosomal gel was 
found with good viscosity, good spreadability and adhesiveness, also it shows maximum drug release and permeation as compared to 
plain gel of fluconazole. In microbiological studies, optimized formulation shows the maximum inhibitory effect as compared to 
plain gel of drug, which concluded that optimized proniosomal gel exerted local and targeted buccal delivery with good fungistatic 
effect than plain gel of fluconazole against Candida albicans. 
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INTRODUCTION  
Oral candidiasis, also known as oral thrush or 
oropharyngeal candidiasis is one of the most common 
human fungal infections of the oral cavity seen in all 
stages of life. The infection is caused by Candida 
albicans, which is dimorphic fungal organism that is 
typically present in the oral cavity
1
. Candida albicans is 
commensal organism and is a part of the normal oral 
flora in about 30% - 50% of the population, a small 
amount of this fungus normally lives in the mouth 
without causing harm. However, when the fungus begins 
to grow uncontrollably, an infection can develop 
2
. Oral 
candidiasis can be a frequent and significant source of 
oral discomfort, pain and aversion to food 
3
.This 
infection is mostly seen in persons with human 
immunodeficiency virus (HIV) and cancer, because of 
their weak immunity 
4
. 
Proniosomal gel preparations are semisolid liquid crystal 
products of non-ionic surfactants prepared by dissolving 
the surfactant in a minimum amount of organic solvent 
(ethanol) and aqueous phase (water). These structures 
are liquid crystalline compact niosomes hybrids that can 
be converted into niosomes immediately upon hydration. 
Proniosomal gel in buccal delivery doesn’t require 
hydration prior to application. Instead these can be 
applied as such or loaded on a gel base 
5
.The gel base 
helps in adhesion of the formulation to the buccal 
mucosa. Proniosomal gel offers a great potential to 
Rao et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2018; 8(4):291-301           
ISSN: 2250-1177                                                                             [292]                                                                             CODEN (USA): JDDTAO 
reduce the side effects of drugs and increase therapeutic 
effectiveness. Proniosomal gel can entrap both 
hydrophilic and hydrophobic drugs. These are generally 
present in transparent, translucent or yellow semisolid 
gel texture, which Makes them physically stable during 
storage and transport (S.H. Abd El-alim; 2014)
6 
. 
Fluconazole (FLZ) is a synthetic antifungal agent, 
belonging to triazole group and most commonly used to 
treat oral fungal infections, such as oral candidiasis 
caused by pathogenic fungi, like Candida albicans 
7
. 
FLZ commercially available as conventional tablets and 
capsules that offer poor bioavailability of the drug due to 
extensive hepatic first pass metabolism and gastric 
instability leading to frequent dosing
8
. Drug delivery by 
the buccal route can bypass the hepatic first pass effect 
and minimize the degradation in the gastric 
environment, thereby affecting enhancement in 
bioavailability. FLZ has log P value of 0.4 and its low 
molecular weight Make it a suitable candidate for 
administration by the buccal route 
9 
. 
The present study was conducted to develop a 
proniosomal gel of FLZ by coacervation phase 
separation method using Span 20, cholesterol, soya 
lecithin and solvents like ethanol and distilled water. 
Optimization was carried out using 3 independent 
variables at 2 different levels were selected using Box 
Behnken design. The independent variables included 
Span 20, distilled water and soya lecithin. The vesicle 
size, percent drug release and entrapment efficiency 
were selected as responses and finally optimized 
proniosomes was characterized by vesicle size, 
entrapment efficiency, in vitro drug release studies, ex 
vivo mucosal permeation studies. After incorporating it 
into 2% Carbopol gel base (1:1), the final proniosomal 
gel was evaluated with viscosity, mucoadhesion and 
spreadability studies, in vitro drug release studies, ex 
vivo mucosal permeation studies, in vitro mucosal 
retention studies and microbiological studies. 
MATERIALS 
FLZ was gifted by Nulife Pharmaceuticals, Pune, India. 
Soya lecithin, cholesterol, Span 20 was purchased from 
S.D. Fine Pvt. Ltd Mumbai, ethanol AR was purchased 
from Loba chemicals Pvt. Ltd, Mumbai. All the reagents 
and solvents used were of analytical grade.  
METHODS 
UV spectrophotometric analytical method:  
Weighed quantity (100 mg) of FLZ was added into 
methanol AR grade (100 ml) in a volumetric flask. 
Different concentrations were prepared as 10, 20, 30, 40, 
50 µg/ml by diluting the stock solution with methanol, 
and analysis was done at 260 nm by UV 
spectrophotometer (Jasco V-550, Japan) against 
methanol as a blank (Figure 1). The validation 
parameters such as precision (intra-day and inter-day 
precision), accuracy, limit of detection (LOD) and limit 
of quantification (LOQ) were studied
10
. 
Drug excipient compatibility studies:  
The compatibility of drug and excipients was checked 
by using Fourier Transform Infra-Red 
Spectrophotometer (JASCO FTIR-460+ 
spectrophotometer), for this the drug and excipients 
were kept in 1:1 ratio at 40˚C ± 75% relative humidity 
for 1 month to check any reaction which may take place 
between drug and excipients
11
.
 
 
Preliminary Studies 
Selection of surfactants and solvents: 
Trial batches (A1-A9) of drug loaded proniosomes were 
prepared by coacervation phase separation method using 
different combinations of surfactants and vehicles along 
with soya lecithin and cholesterol (Table 1). The 
surfactants that were studied included Span 20, Span 60, 
Span 80 and various vehicles included 0.1% aqueous 
glycerol solution, distilled water and phosphate buffer 
pH 6.8. Weighed quantity of FLZ, surfactant, soya 
lecithin and cholesterol was mixed with ethanol. The 
mixture was warmed in a water bath (Make: Metalab) at 
40°C for 10 min. Vehicle was then added to the mixture 
and further warmed to 40°C in water bath for about 10 
min to obtain a clear solution. The mixture was allowed 
to cool to room temperature 25°C until the dispersion 
was converted to gel. The batches were evaluated for 
percent entrapment efficiency, percent drug release and 
percent drug permeation. 
  
Table 1: Trial batches (A1-A9) to select surfactant and vehicles 
      Drug 
(g) 
Cholesterol 
(g) 
Soya 
lecithin 
(g) 
Span 
20 (g) 
Span 
60 (g) 
Span 
80 (g) 
distilled 
water (ml) 
0.1% 
glycerol 
Sol. (ml) 
Phos. 
buffer pH 
6.8 
Ethanol 
(ml) 
A1 0.1 0.1 0.1 - - 0.9 2.5 - - 0.5 
A2 0.1 0.1 0.1 0.9 - - - - 2.5 0.5 
A3 0.1 0.1 0.1 - - 0.9 - 2.5 - 0.5 
A4 0.1 0.1 0.1 - 0.9 - 2.5 - - 0.5 
A5 0.1 0.1 0.1 0.9 - - 2.5 -  0.5 
A6 0.1 0.1 0.1 0.9 - - - 2.5  0.5 
A7 0.1 0.1 0.1 - 0.9 - - - 2.5 0.5 
A8 0.1 0.1 0.1 - 0.9 - - 2.5  0.5 
A9 0.1 0.1 0.1 - - 0.9 - - 2.5 0.5 
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Experimental Design 
Effect of 3 independent variables at 2 different levels on 
various responses was evaluated using Box-Behnken 
design. These independent variables included Span 20, 
distilled water and soya lecithin with percent entrapment 
efficiency, vesicle size and percent drug release (% 
release 3h), as responses. Based on 2 levels, 15 batches 
(F1- F15) were prepared by Design Expert Software 
(Design Expert 11, Stat-Ease and Minneapolis, MN). 
The optimized batch was selected on the basis of high 
entrapment efficiency; low vesicle size and high percent 
drug release (Table 3). The optimized batch of 
proniosomes was further incorporated into 2% w/w 
Carbopol gel 934. Briefly, required quantity of Carbopol 
934 was mixed with distilled water and mixed using 
magnetic stirrer (Make: Remi, Model: 1MLH) at 50 rpm 
till the Carbopol dissolved. To this solution, the 
optimised proniosomes was added in a 1:1 ratio with 
continuous stirring till a homogenous gel was obtained. 
This gel was subjected to further evaluation. 
Evaluation of Drug Loaded Proniosomes 
Vesicle size:    
The mean vesicle size of all design batches was analyzed 
by Malvern zeta seizer (Model- NanoZS90) based on the 
principle of dynamic light scattering. The proniosomes 
(1 ml) were diluted with glycerine and the vesicle size 
was measured.
12
 
Percent Entrapment Efficiency:  
Proniosomes (0.1 g) were diluted with 10 ml of 
phosphate buffer pH 6.8. The aqueous dispersion was 
sonicated in a sonicator bath (Make-Labman, Model-
LMUC-2) for 10 min, followed by centrifugation 
(Make- REMI, Model- RM-12CBh) at 6,000 rpm at 
20°C for 1 h. The supernatant was collected and assayed 
by UV spectrophotometer for un-entrapped drug at 260 
nm. The percentage of drug encapsulation (%EE) was 
calculated by the following equation: 
13
 
                       
 
                          
          
      
In vitro drug release and ex vivo mucosal permeation 
study: 
 
In vitro drug release study and ex vivo mucosal 
permeation study was performed using Franz diffusion 
cell (Make- Orchid Scientifics). In these studies two 
different membranes were used, such as cellophane 
membrane (Pall Life Sciences, India Pvt. Ltd.) for in 
vitro drug release study and fresh oral goat mucosa for 
mucosal permeation study. The cellophane membrane 
was soaked for 24 h prior to diffusion study in phosphate 
buffer pH 6.8. The proniosomes (300 mg) containing 5 
mg FLZ was placed in the donor compartment. Both 
receptor and donor compartment consisted of phosphate 
buffer pH 6.8 at a temperature of 37±2 °C under 
constant magnetic stirring for 3 h. Aliquots of 1ml were 
withdrawn every half hour from receptor compartment 
and replaced with equal volume of diffusion media to 
maintain constant receptor phase volume. The samples 
were suitably diluted and assayed for drug content using 
UV spectrophotometer at 260 nm. From the total drug 
content cumulative percent drug release in 3 h and 
permeation coefficient was calculated.
14, 15
 
Drug content:  
The proniosomes (0.1g) were diluted with 10 ml of 
phosphate buffer pH 6.8, this dispersion was sonicated 
(Make-Labman, Model-LMUC-2) for 10 min at 30°C 
and absorbance was measured at 260 nm. The total drug 
content was calculated by the following equation: 
16, 17
 
             
                 
               
      
Evaluation of Optimized Proniosomal Gel 
The optimized proniosomal gel was subjected to various 
studies such as viscosity, in vitro drug release and ex 
vivo mucosal permeation studies, in vitro mucosal 
retention studies, mucoadhesive strength and 
spreadability studies, microbiological studies, Stability 
studies.          
The in vitro and ex vivo studies for optimized 
proniosomal gel and plain gel of FLZ were performed 
using same procedure as for proniosomes.   
In vitro mucosal retention studies:  
The amount of drug retained in buccal mucosa was 
determined after permeation studies (3h), by washing the 
mucosa with methanol and homogenizing in presence of 
methanol using homogenizer (bio lab instruments bl244) 
at 4000 rpm for 5 min. the tissue dispersion was 
centrifuged (make- Remi, model- rm-12cbh) at 9000 
rpm for 15 min and the supernatant was filtered through 
whatman filter paper (0.45µ) for analysis of drug content 
by UV spectrophotometer at 260nm.
18
 
Viscosity:  
Viscosity of proniosomal gel was determined using 
Brookfield viscometer (Make- Brookfield, Model- DV II 
+ Pro viscometer) Spindle number 7 was attached to the 
viscometer and dipped it into flask containing 
proniosomal gel (50 g), parameters such as rpm and 
spindle number was set as (20 rpm, spindle no.7) and 
viscosity was recorded.
19
 
Mucoadhesive strength and spreadability of 
proniosomal gel:  
The mucoadhesive strength and spreadability of 
proniosomal gel was determined using Brookfield 
texture analyser (CT 100). Mucoadhesive strength of 
formulation was determined by measuring force required 
to detach mucous membrane from the formulation. Fresh 
goat buccal mucosa was attached to the upper probe of 
the instrument; 2 g of proniosomal gel was place in 
lower chamber. The upper probe was slowly moved 
downward to touch the surface of the proniosomal gel. A 
force required to ensuring intimate contact between the 
mucosa and proniosomal gel was recorded. The 
spreadability was determined by taking proniosomal gel 
in the cup of the texture analyser, previously aligned 
with the upper probe. The upper probe was slowly 
dipped into cup containing proniosomal gel. The 
spreadability of formulation was determined by 
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measuring force required to spread the formulation. The 
hardness value of optimized proniosomal gel was 
recorded.
 20, 21
  
Microbiological evaluation:  
The microbiological studies were performing to 
determine the effect of proniosomal gel against Candida 
albicans, and were compared with the effect of plain gel 
containing FLZ and standard drug solution. For this 
study, 20 ml of sterilized soya bean casein digest agar 
was poured into six petriplates and inoculated with 
Candida albicans (100 µl per plate) was poured in six 
sterilized petriplates and three cups of 5 mm diameter 
were made using sterile cork borer in each petriplate. 
Different concentrations of proniosomal gel formulation 
(1.5 µg/µl, 3.12 µg/µl, 6.5 µg/µl,12 µg/µl and 25 µg/µl) 
were prepared in dimethyl sulfoxide (DMSO) and 
accurately 25 µl of each dilution was transferred to cups 
in laminar air flow unit. Likewise same concentrations 
for plain gel and standard drug solution was prepared 
and transferred to cups aseptically. The prepared 
petriplates were maintained in refrigeration (5°C) for 20 
min for facilitating diffusion of the solutions in to the 
medium and then incubated at 37°C for 72 h in incubator 
(Make-VHS Electronics, Model-Bacteriological 
incubator). The diameter of zone of inhibition 
surrounding each of the wells was recorded.
 22, 23, 24
 
 Stability studies:  
Stability studies was carried out as per ICH guideline, by 
storing the optimized proniosomal gel at various 
temperature conditions like refrigeration on (4˚C), room 
temperature (25˚±0.5˚C) and elevated temperature 
(45˚±0.5˚C and 70 % RH) from a period of 1 month to 3 
months. Drug content and variation in the average 
vesicle diameter were periodically monitored (after 1, 2 
and 3 months).
 25
 
RESULTS AND DISCUSSION 
UV spectrophotometric Analytical Method: 
The calibration curve showed good linearity in the 
Beer’s law limit of 10-50 μg/ml in methanol AR grade 
for FLZ with correlation coefficient (r
2
) of 0.990 (Figure 
1). The method was validated by different parameters 
which included precision (intra-day and inter-day 
precision), accuracy, limit of detection (LOD) and limit 
of quantification (LOQ).The percent relative standard 
deviation (% RSD) values of interday and intraday 
precision were found to be 1.924 and 1.24275 for 10 
μg/ml. The mean recovery (n= 3) was found to be 94.2 
% (% RSD = 1.18) for the drug FLZ showing the 
accuracy of the method. Limit of detection (LOD) and 
limit of quantification (LOQ) was found to be 1.1μg/ml 
and 3.33 μg/ml. 
 
Figure 1: Calibration curve of Fluconazole analysed by 
UV-Vis Spectrophotometer 
Drug excipient compatibility studies:    
This study was carried out to check the interaction of 
drug and excipients. The characteristic IR peaks 
observed for FLZ include OH stretch, CH2 stretching, 
CH (aromatic stretching), C = N stretch , CH (aromatic 
bending), and C-F stretch, at 3072.41 cm
-1
, 1604.78 cm
-
1
, 1134.82 cm
-1
 and 901.28 cm
-1. 
The FT-IR spectra of 
binary mixture drug with cholesterol, soya lecithin, Span 
20 and Carbopol 934 showed no significant changes 
which indicated that there was no interaction between 
FLZ and other excipients. 
 
 
Figure 2: Compatibility studies of binary mixtures of drug and excipients (1:1 ratio) with 
A: Drug, B: cholesterol, C: Carbopol 934, D: Span 20, E: soya lecithin and F: physical mixture. 
Preliminary Studies 
Selection of surfactant and vehicle: 
Trial batches of proniosomes were prepared to select 
surfactant and vehicle. Various surfactants that were 
studied included Span 20, Span 60, Span 80 and 
vehicles included 0.1% aqueous glycerol solution, 
distilled water and phosphate buffer pH 6.8 along with 
other ingredients such as soya lecithin, cholesterol and 
ethanol. Total nine trial batches (A1-A9) were prepared 
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and each batch was evaluated for percent entrapment 
efficiency, percent drug release and percent drug 
permeation. In all the batches, highest entrapment 
efficiency in each series of proniosomes were found in 
the following order i.e. Span 20 > Span 60 > Span 80 
respectively. The entrapment efficiency of proniosomes 
depends on the value hydrophilic lipophilic balance 
(HLB) of surfactants. Surfactant with HLB value 8.6 
gives highest entrapment. The entrapment efficiency 
decreases as the HLB value decreases from 8.6 to 1.7. 
(Gannu P. Kumar et. al, 2011). 
26
 
The percent drug release of proniosomes was depending 
on surfactants which formed less rigid and high 
permeable bilayer. The percent drug release of 
Proniosomes prepared with Span 20 was slower than 
those prepared using Span 60 and Span 80. Hence Span 
20 was showing high percent release through the 
vesicles (Ruba Bnyan et. al, 2018).
27
  
The mucosal permeation of proniosomes was depending 
on gel transition temperature of surfactants. The 
surfactant with higher transition temperature like Span 
60 and Span 80 was penetrate slowly, the reason behind 
that, the surfactant needed higher temperature to formed 
disordered liquid crystalline state and to completely 
fluidized and hence they were less permeable. Whereas 
the contrary happen in case of surfactant with low 
transition temperature likes Span 20 and hence the 
permeation was increased (Thomas Litha et. al, 2011).
28
 
The batch (A5) containing Span 20 (HLB 8.6) and 
distilled water showing high entrapment efficiency i.e. 
(96%), high percent drug release (84.30%) and high 
permeation rate, was selected for further studies. (Table 
2)
                   Table 2: Results of trial batches for selection of vehicle and surfactant (*n = 3, mean ± SD) 
Batch 
No. 
Batch  *Entrapment efficiency 
(%)  
*Cummulative%release  
(3 h)  
*Permeability 
(cm/hr)  
A1  (Span 80+ distilled water)  73.25 ± 0.085 78.16 ± 0.584 2.8822 ± 0.099 
A2 (Span 20+ Phosphate Buffer) 96.83 ± 1.012 60.83 ± 0.852 3.4244 ± 0.092 
A3 (Span 80+ Glycerol Solution) 68.63 ± 3.052 74.33 ± 0.121 3.2666 ± 0.525 
A4 (Span 60+ distilled water)  80.09 ± 0.948 60.66 ± 1.965 1.6044 ± 0.066 
A5 (Span 20+ distilled water)  96.04 ± 2.078 84.30 ± 1.002 3.6266 ± 0.292 
A6 (Span 20+ Glycerol Solution)  93.77 ± 1.179 60.33 ± 0.855 2.9711 ± 0.312 
A7 (Span 60+ Phosphate Buffer)  85.54 ± 2.092 59.00 ± 0.254 1.4244 ± 0.051 
A8 (Span 60+ Glycerol Solution)  92.68 ± 0.928  57.05 ± 0.145 1.4577 ± 0.072 
A9  (Span 80+ Phosphate Buffer)  74.83 ± 1.064 71.05 ± 0.845 2.9511 ± 0.291 
 
Box Behnken Batches of Proniosomes 
Effect of 3 independent variables at 2 different levels on 
various responses was evaluated using Box-Behnken 
design. These independent variables included Span 20, 
distilled water and soya lecithin with percent entrapment 
efficiency, vesicle size and percent drug release (% 
release 3h), as responses. Based on 2 levels, 15 batches 
(F1-F15) were prepared by Design Expert Software 
(Design Expert 11, Stat-Ease, Minneapolis, MN).The 
measured responses were used to construct 3D response 
surface plot to establish the relationship between 
variables and their interaction. Analysis of variance 
(ANOVA) was used to validate the design 
. 
Table 3: Results of batches for optimization of formulation (*n = 3, mean ± SD) 
  Factor A  Factor B  Factor C  Response (Y1) Response (Y2) Response 3 (Y3)  
Std  Run  
A:Span 
20  
B:distilled 
Water  
C:soya 
Lecithin  
*Entrapment 
efficiency  
*Vesicle size  
*Cumulative 
release  
  g ml g  %  µm  %  
F1  1 0.45 0.8 0.125 84.1 ±0.212  3.5 ± 0.586 61.66 ± 0.845 
F2  2 1.8 0.8 0.125 91.8 ± 0.520 3.0 ± 0.255 73.66 ± 0.126 
F3  3 0.45 3.2 0.125 71.1 ±1.115 4.0 ± 0.754 63.66 ± 1.985 
F4  4 1.8 3.2 0.125 94.43 ±2.010 3.2 ± 0.295 80.83 ± 1.485 
F5  5 0.45 2 0.05 76.4 ± 0.912  5.2 ± 1.845 63.06 ± 2.156 
F6  6 1.8 2 0.05 93.23 ± 1.220  2.6 ± 0.211 81.33 ± 0.466 
F7 7 0.45 2 0.2 67.91 ± 1.010 3.1 ± 0.120 59.16 ± 1.948 
F8  8 1.8 2 0.2 95.96 ± 2.001 4.2 ± 0.369 75.16 ± 0.141 
F9  9 1.125 0.8 0.05 93.01 ± 3.017 7.1± 2.101 73.83 ± 0.456 
F10  10 1.125 3.2 0.05 93.88 ± 1.012 3.8 ± 0.148 78.5 ± 2.012 
F11  11 1.125 0.8 0.2 96.83 ± 0.821 3.0 ± 0.456 80.16 ± 1.025 
F12  12 1.125 3.2 0.2 96.83 ± 0.911 2.1 ± 0.210  85.66 ± 2.014 
F13  13 1.125 2 0.125 88.53 ± 1.014 6.6 ± 1.142 69.66 ± 1.254 
F14  14 1.125 2 0.125 88.53 ± 1.014 6.6 ± 3.152 69.66 ± 0.452 
F15  15 1.125 2 0.125 88.53 ± 1.014 6.6 ± 1.294 69.66 ± 0.422 
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Evaluation Parameters of Box-Behnken Batches 
Percent entrapment efficiency: (Y1) 
Entrapment efficiency is one of the critical parameters 
that will affect the performance of the drug delivery 
form.  
All the factorial batches (F1 to F15) were found to have 
significant effect on the entrapment efficiency (Y1). The 
mean percent entrapment efficiency of all Box-Behnken 
batches was found to be in range 67.91% - 96.83% 
(table 3). The effect of amount of Span 20 (A) was 
found to be significant (p< 0.05), where the coefficient 
was found to be positive (Eq. 1). This implied that, an 
increase in amount of Span 20 (A) leads to increase in 
entrapment efficiency (Y1) whereas all other factors 
were found to have an insignificant effect on entrapment 
efficiency (p > 0.05).  
Y1 = 88.53 +12.05 A -1.63 B -1.99 C +3.03 AB +7.03 
AC -0.2175 BC -9.13 A
2
+6.85 B
2 
-0.2438 C
2
 
(Eq. 1).
 
Surfactant is the main component responsible for vesicle 
formation significantly increased the entrapment 
efficiency. This might be attributed to the increase in the 
number of formed proniosomes and consequently the 
volume of the hydrophobic bilayer domain, the available 
housing for entrapment FLZ hydrophobic drug. 
(Gagandeep Benipal, 2015)
 29
. Besides this, proniosomes 
are capable of encapsulating both hydrophilic and 
hydrophobic drugs. Fluconazole, though having a low 
log P (0.4) is poorly water soluble due to the presence of 
two triazole rings which impart significant basicity, to 
the molecule making it poorly water soluble.  
(Parthibarajan et al; 2013) 
30
, (Ning et al; 2005) 
31
. 
 Percent entrapment efficiency: (Y1) 
 
 
Figure 3:  A1and A2 represents the response surface curve plots for the entrapment efficiency (Y1) 
 
Vesicle size: (Y2) 
Smaller vesicle size was advantageous to improve the 
penetration of vesicles into the mucosa.  
The mean vesicle size (Y2) of all factorial batches of 
proniosomes were found to be between (2.1 ±0.214 µm) 
to (7.1 ±2.101 µm). The effect of amount of Span 20 
(A
2
) was found to be significant (p < 0.05) having a 
negative coefficient. This implied that, an increase in 
amount of Span 20 (A) leads to decrease in vesicle size 
(Y2) it might be due to increasing surfactant 
concentration can also lead to an increase in charge, 
which in turn reduces vesicle aggregation and enhances 
the stability of the system
29
. The effect of volume of 
distilled water (B
2
) was found to be significant (p< 
0.05), indicating decrease in vesicle size (Y2) with 
increase in volume of distilled water (B). This is due to 
the volume of hydration medium affects the vesicle size 
(Gannu P. Kumar et. al; 2011)
 26
. Whereas effect of all 
other factors was found to be non significant.  
Y2 = +7.20 -0.1625 A -0.6125 B -0.7750 C +0.3000 AB 
+0.9250 AC +0.5750B C -2.17 A
2 
-1.97 B
2 
-1.25 C
2   
(Eq. 2). 
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Figure 4:  B1, B2 and B3 represents the response surface curve plots for the vesicle size (Y2 ) 
Percent drug release: (Y3)  
The percent drug release is one of the important 
characteristics affecting the performance of 
proniosomes.  
The percent drug release (Y3) of all factorial batches of 
proniosomes was found to be between 59 - 85 % in 3 h. 
The effect of amount of Span 20 (A) was found to be 
significant (p< 0.05) and the coefficient was found to be 
positive. This implied that, an increase in amount of 
Span 20 (A) leads to an increase in percent drug release 
(Y3) (Gagandeep Benipal; 2015)
 29
. This is due to less 
rigidity and highly permeable bilayer formed by Span 
20 (Ruba Bnyan et. al; 2018)
 27
. Whereas effect of 
amount of all other factors was found to be non 
significant.  
Y3= +69.66 +7.86 A +2.42B +0.3500 C +1.29AB -
0.4025AC +0.2075BC -4.71A
2
 +5.00B
2 
+4.87C
2  
(Eq. 3). 
 
 
Figure 5: C1, C2 and C3 represent the response surface curve plots for the % drug release (Y3) 
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Selection of optimized formulation and validation 
studies 
Selection of optimized formulation for proniosomes 
were carried out, where the various trials were made to 
attain the goals like minimum vesicle size, maximum of 
entrapment efficiency and maximum of cumulative 
percent drug release. The optimized batch was chosen by 
numeric optimization using desirability function. The 
constraints set for numerical optimization of 
proniosomes included entrapment efficiency (Y1>80%), 
vesicle size (Y2<10µm) and cumulative percent drug 
release (Y3>70%). Three different optimized batches of 
proniosomes generated by the software were prepared 
and evaluated to select one batch based on their 
desirability function. The selected optimized batch of 
proniosomes contained amount of Span 20 (1.125 g) 
(A), distilled water (3.2 ml) (B) and soya lecithin (0.2 
g)(C) exhibiting an entrapment efficiency of (96.1%), 
vesicle size of (2.6 µm), and cumulative percent drug 
release of (85%) with desirability 1. Thus, the 
formulation batch giving maximum entrapment 
efficiency (Y1), minimum vesicle size (Y2) and 
maximum cumulative percent drug release (Y3) was 
chosen as the optimized batch. 
  
Table 4: Box-Behnken design layout for optimization of proniosomes 
Factors Levels Responses 
-1 0 +1 
Factor A: Span 20 (g) 0.45 1.125 1.8 % Entrapment efficiency 
Vesicle size 
Percent drug release 
Factor B: distilled water (ml) 0.8 2 3.2 
Factor C: soya lecithin (g)  0.05 0.125 0.2 
 
Evaluation of Optimized Proniosomes 
Besides the three responses (Y1, Y2 and Y3), the selected 
optimized batch of proniosomes were characterized by, 
ex vivo mucosal permeation and drug content. The drug 
content of optimized proniosomal gel was found to be 
89%. 
Ex vivo mucosal permeation studies:  
The ex vivo mucosal permeation studies (for 3 h) of 
optimized proniosomes were carried out using fresh goat 
buccal mucosa as permeation membrane by Franz 
diffusion cell (Make- Orchid Scientifics) at 37°C in 
phosphate buffer pH 6.8. The percent drug permeated 
was found to be 85.67 % in 3 h and flux was found to be 
394.09 μg/cm2h which shows high permeation of drug 
through the goat buccal mucosa. This is because lower 
the transition temperature better is the permeability as 
disordered liquid crystalline state is easily formed, 
resulting in a fluid vesicle membrane and hence higher 
permeation of drug. (Thomas Litha et. al; 2011).
28
 
Evaluation Optimized Proniosomal Gel 
In vitro drug release and ex vivo mucosal permeation 
study:- 
The in vitro drug release studies (for 3 h) of optimized 
proniosomal gel and plain gel of FLZ were carried out 
using cellophane membrane (Pall Life Sciences, India 
Pvt. Ltd.) by Franz diffusion cell (Make- Orchid 
sanctifies) at 37°C in phosphate buffer pH 6.8. The in 
vitro drug release from optimized proniosomal gel was 
found to be 77.08 % in 3 h and for plain gel it was 
51.04% in 3 h. The percent drug release through the 
optimized proniosomal gel was 26.04% high due to 
presence of Span 20 in proniosomal gel.(fig 6) Span 20 
is reported to form vesicles with relatively less rigidity 
and formed highly permeable bilayer (Ruba Bnyan et. al; 
2018)
 27
. This could explain the higher drug release. At 
the same time the solubility of FLZ is believed to be 
enhanced in the niosomes wherein the drug could 
possible be entrapped in the bilayers of the vesicles 
(Ruba Bnyan et. al; 2018)
 27
. 
The mucosal permeation of proniosomal gel through 
goat buccal mucosa was found to be 84.30 % in 3 h and 
flux was found to be 387.8 μg/cm2.h, where as for plain 
gel it was 59.87% in 3 h, and flux was found to be 
283.10 μg/cm2.h (fig 6). This implied that proniosomal 
gel displayed nearly 25% higher release through 
cellophane membrane as well as high permeation 
(Thomas Litha et. al; 2011)
28 
of drug through the goat 
buccal mucosa as compared to plain gel of FLZ.  Span 
20 and soya lecithin in the proniosomes are responsible 
for the good permeability of FLZ. The transition 
temperature of the surfactant plays an important role in 
vesicle structure. Lower the transition temperature better 
is the permeability as disordered liquid crystalline state 
is easily formed, resulting in a fluid vesicle membrane 
and hence higher permeation of drug. Span 20 has a 
transition temperature (Thomas Litha et. al; 2011)
 28 
hence it positively influences permeation of drug. Soya 
lecithin contains oleic and linoleic acid and hence it acts 
as a permeation enhancer as the double bond in the 
unsaturated fatty acids will cause the chain to bend by 
providing the conformational rotation to give cis/trans 
conformation. This will result in lower critical packing 
parameter and hence increased permeability, as the 
molecules are not tightly packed (Thomas Litha et. al; 
2011). 
28 
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Figure 6: ‘A’ represents the in vitro percent release of optimized proniosomal gel and plain gel of FLZ and ‘B’ 
represents the ex vivo permeation of optimised proniosomal gel and plain gel of FLZ 
 
In vitro mucosal retention studies:  
The amount of drug retained in buccal mucosa was 
determined after permeation studies (3h), and it was 
found to be 763 µg at the end of 3 h. This indicates that 
significant amount of drug is retained in the mucosal 
layers signifying continued therapeutic action even after 
3 h. Since oral candidiasis is a superficial infection, the 
higher drug retention is advantageous for the therapy. 
The molecular mass of FLZ is 306.3 daltons and it is 
reported that only small molecules with mass less than 
100 daltons can cross the epithelial intercellular 
permeability barrier rapidly (Lee Martin et. al 2003)
32
. 
Thus we may presume that though proniosomes contain 
surfactants which are known to be penetration 
enhancers, FLZ, by virtue of its molecular size will 
remain in the superficial mucosal layers for longer 
duration of time. By comparing permeability data with 
retention studies, we may infer that soya lecithin and 
span 20 will facilitate penetration of drug through the 
fungal cell wall. It is also reported that despite the low 
porosity of fungal cell wall, different types of vesicles 
can travel through wall due to its deformable and 
viscoelastic properties (Louise Walker, et. al 2003).
33
 
Viscosity:  
Viscosity of optimized proniosomal gel (50 g), was 
determined using Brookfield viscometer (20 rpm, 
spindle no.7) and viscosity was found to be 54733±550 
cps. The viscosity of 2% carbopol gel was found to be 
32666 ± 411 cps whereas of the proniosomes, it was 
1578 ± 681cps. Thus it is evident that the overall 
viscosity of the proniosomal gel is higher which will 
ensure prolonged residence of the formulation in the oral 
cavity.  
Mucoadhesive strength and spreadability of 
proniosomal gel:-  
The mucoadhesive strength and spreadability of 
proniosomal gel was determined using Brookfield 
texture analyser (CT 100) by measuring force required 
to detach mucous membrane from the formulation. 
Mucoadhesiveness of proniosomal gel was found to be 
8.20 g which is adequate to ensure longer residence time 
in the oral cavity. Carbopol bind to oligosaccharide 
chain present in mucosal membrane, resulting in 
moderate bioadhesive force which enhanced gel 
strength. the spreadability of proniosomal gel were 
determined by texture analyser. The spreadability of 
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proniosomal gel was determined by measuring force 
required to spread the formulation, which depends on 
hardness of proniosomal gel. As hardness increases 
spreadability of proniosomal gel decreases. The hardness 
value of optimized proniosomal gel was found to be 
24.10 g. Spreadability is necessary to enable the 
formulation to cover as much mucosal area as possible 
and also to enable continued release of the drug.   
Microbiological evaluation: 
The microbiological assay for Candida albicans was 
carried out for optimized proniosomal gel and compared 
with plain gel formulation and pure drug solution. The 
diameter of zone of inhibition obtained with plain gel, 
optimized proniosomal gel and drug solution is shown in 
(figure 7). The standard drug solution (25µg/µl) showed 
zone of inhibition of 15 mm whereas the same was 
found to be 9 mm for plain gel containing 25 µg/µl drug. 
The zone of inhibition for optimized proniosomal gel 
was measured as 13 mm. This indicated that optimized 
proniosomal gel showed good inhibitory effect against 
Candida albicans than that of the plain gel. These results 
confirm that the solubility of FLZ is enhanced in the 
proniosomes and that the drug is able to permeate 
through the vesicles and exert its fungistatic effect 
against Candida albicans, by inhibiting the cytochrome 
P-450 dependent enzyme lanosterol demethylase which 
is required for the conversion of lanosterol to ergosterol. 
Ergosterol is essential for fungal cell membrane integrity 
and function, resulting in inhibition of fungal growth 
(Mahipal Sinnollareddy, 2011).
34
 
 
Figure 7: Zone of inhibition in drug solution (A), 
proniosomal gel formulation (B) and plain gel (C) 
Stability studies: 
The optimized batch of proniosomal gel was subjected 
to physical and chemical stability studies at 40˚C ± 75% 
RH for 3 months and evaluated at intervals of 0, 1, 2 and 
3 months. No significant differences in organoleptic 
properties were observed. Insignificant changes in FLZ 
content were seen. Thus, these studies assured that 
formulated optimized batch of proniosomal gel was 
stable up to 3 months. 
 
Table 5: Drug content of optimized proniosomal gel for stability studies.  (*n=3, mean ± SD) 
Parameter For 0 day for 1st month for 2
nd
 month for 3
rd
 month 
Drug content 96.06± 1.393 96.00± 1.10 95.34± 1.30 94.65± 1.218 
 
 
CONCLUSION 
Oral candidiasis, the most common fungal infection, 
caused by the yeast Candida albicans was treated with 
optimized proniosomal gel of FLZ, which was used for 
applied over buccal mucosa. Hence it showed good 
targeted and local action. The complete summary of 
present research work concluded that the optimized 
batch of proniosomal gel shows good storage stability, 
good fungicidal activity against Candida albicans as 
compared to plain gel of FLZ. Due to their vesicular 
content proniosomal gel gives high permeation rate, high 
percent drug release and highly retention of FLZ in 
buccal mucosa as compared to plain gel of FLZ.  
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